BON-110 / Huahui Health, BeOne Medicines - LARVOL DELTA

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=299 | Recruiting | Sponsor: Huahui Health | Not yet recruiting ➔ Recruiting | N=56 ➔ 299 | Trial primary completion date: Aug 2028 ➔ Aug 2027

Enrollment change • Enrollment open • First-in-human • Trial primary completion date • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Urothelial Cancer

BON-110 (PD-1xVEGF-AxCTLA-4 trispecific antibody): Initiated first-in-human study. (Businesswire)

First-in-human • Trial status • Non Small Cell Lung Cancer

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: Huahui Health

First-in-human • New P1 trial • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Urothelial Cancer

Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160 (The Manila Times) - "Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide. Pursuant to the agreement, BeOne Medicines will pay Huahui Health an upfront payment of USD 20 million. Upon exercise of the option by BeOne Medicines, Huahui Health will be entitled to receive an additional USD 100 million option exercise payment."

Licensing / partnership • Oncology

A symmetrical hexavalent trispecific antibody, HH160, targeting PD-1, CTLA-4 and VEGF-A for enhanced anti-cancer effects (AACR 2025) - "Background: Antiangiogenic agents, such as the anti-vascular endothelial growth factor A (VEGF-A) antibody Bevacizumab, are among the first targeted therapies in cancer treatment. Our study demonstrates that HH160 is a promising trispecific antibody for simultaneously targeting PD-1, CTLA4 and VEGF-A. It has the potential to harness the synergistic anti-tumor mechanisms, overcome resistance to monotherapy, and simplify the dosing regimen, supporting further development and clinical investigation."

Trispecific • Cervical Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNG • IL2